Skip to main content
Dana-Farber
  • person
  • dana-farber.org
  • Search
  • Featured Specialties
    • Breast Oncology
    • Gastrointestinal Oncology
    • Genitourinary Oncology
    • Gynecologic Oncology
    • Hematologic Oncology
    • Pediatric Oncology
  • Find a Physician
  • Find a Clinical Trial
  • Refer a Patient
  • Contact Us

Sara M. Tolaney, MD, MPH

Medical Oncology

Sara M. Tolaney, MD, MPH

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on the development of novel therapies in the treatment of breast cancer.

View Full Profile


Related Videos

Sara Tolany, MD Shares the Latest Breast Cancer Research Video

Sara Tolany, MD Shares the Latest Breast Cancer Research

Results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast cancer.

Sara Tolaney, MD Shares New Study Results in Breast Cancer Video

Sara Tolaney, MD Shares New Study Results in Breast Cancer

Significant improvement in overall survival (OS) results seen in phase 3 TROPiCS study. Sacituzumab Govitecan improved OS from 11.2 months to 14.4 months compared to treatment of choice chemo.

Sara Tolany, MD shares the latest Breast Cancer Research Video

Sara Tolany, MD shares the latest Breast Cancer Research

Breast Cancer: Results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast cancer.

Breast Cancer Research at ESMO Video

Breast Cancer Research at ESMO

Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.

Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials Video

Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials

Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.

COVID-19 Vaccine Study in Cancer Patients Video

COVID-19 Vaccine Study in Cancer Patients

Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.

ASCO22: Breast cancer research by Sara Tolaney, MD Video

ASCO22: Breast cancer research by Sara Tolaney, MD

Breast cancer phase 3 study results TROPiCS-02 at #ASCO22: Dana-Farber's Sara Tolaney, MD, senior author, says research shows new antibody-drug conjugate produced improved progression-free survival rates compared to chemotherapy in HR+/HER2-neg ...

Connect with us

Facebook_DanaFarber_Blue_icon X_DanaFarber_Blue_icon Instagram_DanaFarber_Blue_icon Youtube_DanaFarber_Blue_icon LinkedIn_DanaFarber_Blue_icon
  • About Us
  • Research
  • Medical Oncology Spotlight
  • Find a Clinical Trial
  • Find a Physician
  • Refer a Patient
  • Clinical Resources
  • Dana-Farber
Powered by BroadcastMedBROADCASTMED